Plain-English translation of NCT05487391 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Carcinoma, Non-Small-Cell Lung research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called QL1706 combined with standard chemotherapy in people who have had surgery to remove early-stage lung cancer. Half of the participants will receive QL1706 plus chemotherapy, while the other half will receive a placebo (a fake medication) plus the same chemotherapy. Researchers want to see if adding this medication helps prevent cancer from coming back.
Even after surgery successfully removes the tumor, early-stage lung cancer can sometimes return. This trial is designed to find out whether this new treatment can help reduce that risk and help patients live longer without their cancer returning.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either QL1706 plus chemotherapy or placebo plus chemotherapy every 3 weeks by IV infusion. You'll continue treatment for several months and attend regular clinic visits for check-ups, blood tests, and imaging scans to monitor your health and how well the treatment is working. The study team will track you for a significant period to see if the medication helps prevent your cancer from returning.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China